Report Tools

Pharmaceuticals - North America (NAFTA) Industry Guide

Published: November 2012 · Publisher: MarketLine
Pharmaceuticals - North America (NAFTA) Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the North American Free Trade Agreement (United States, Canada, and Mexico) countries.
Report Type Industry Guides
Language English
Format Electronic (PDF)
Pages91
Frequency Updated Annually
Availability Will be emailed within 1 business day
Reference No. 0109-1048
Price € 599,00
Options
  • Description
  • Table of Contents
  • Ask a Question
Pharmaceuticals - North America (NAFTA) Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the North American Free Trade Agreement (United States, Canada, and Mexico) countries. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report

* Contains an executive summary and data on value, volume and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Compares data from the US, Canada and Mexico, alongside individual chapters on each country. .

* Includes a five-year forecast of the industry

Highlights

The pharmaceuticals industry within the NAFTA countries had a total market value of $298.2 billion in 2011. Mexico was the fastest growing country, with a CAGR of 5.5% over the 2007-11 period.



Within the pharmaceuticals industry, US is the leading country among the NAFTA bloc, with market revenues of $262.7 billion in 2011.

US is expected to lead the pharmaceuticals industry in the NAFTA bloc, with a value of $299.5 billion in 2016.

Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition

The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors).
Any currency conversions used in the production of this report have been calculated at constant 2011 annual average exchange rates.
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
TABLE OF CONTENTS
Introduction 8
What is this report about? 8
Who is the target reader? 8
How to use this report 8
Definitions 8
NAFTA Pharmaceuticals Industry Outlook 9
Pharmaceuticals in Canada 12
Market Overview 12
Market Data 13
Market Segmentation 14
Market outlook 16
Five forces analysis 17
Macroeconomic indicators 25
Pharmaceuticals in Mexico 27
Market Overview 27
Market Data 28
Market Segmentation 29
Market outlook 31
Five forces analysis 32
Macroeconomic indicators 40
Pharmaceuticals in The United States 42
Market Overview 42
Market Data 43
Market Segmentation 44
Market outlook 46
Five forces analysis 47
Macroeconomic indicators 55
Company Profiles 57
Leading companies 57
Appendix 90
Methodology 90

LIST OF TABLES
Table 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2007-16 9
Table 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2007-16 10
Table 3: NAFTA countries pharmaceuticals industry, revenue ($bn), 2007-16 11
Table 4: Canada pharmaceuticals market value: $ billion, 2007–11 13
Table 5: Canada pharmaceuticals market geography segmentation: $ billion, 2011 14
Table 6: Canada pharmaceuticals market share: % share, by value, 2011 15
Table 7: Canada pharmaceuticals market value forecast: $ billion, 2011–16 16
Table 8: Canada size of population (million), 2007–11 25
Table 9: Canada gdp (constant 2000 prices, $ billion), 2007–11 25
Table 10: Canada gdp (current prices, $ billion), 2007–11 25
Table 11: Canada inflation, 2007–11 26
Table 12: Canada consumer price index (absolute), 2007–11 26
Table 13: Canada exchange rate, 2007–11 26
Table 14: Mexico pharmaceuticals market value: $ billion, 2007–11 28
Table 15: Mexico pharmaceuticals market geography segmentation: $ billion, 2011 29
Table 16: Mexico pharmaceuticals market share: % share, by value, 2011 30
Table 17: Mexico pharmaceuticals market value forecast: $ billion, 2011–16 31
Table 18: Mexico size of population (million), 2007–11 40
Table 19: Mexico gdp (constant 2000 prices, $ billion), 2007–11 40
Table 20: Mexico gdp (current prices, $ billion), 2007–11 40
Table 21: Mexico inflation, 2007–11 41
Table 22: Mexico consumer price index (absolute), 2007–11 41
Table 23: Mexico exchange rate, 2007–11 41
Table 24: United States pharmaceuticals market value: $ billion, 2007–11 43
Table 25: United States pharmaceuticals market geography segmentation: $ billion, 2011 44
Table 26: United States pharmaceuticals market share: % share, by value, 2011 45
Table 27: United States pharmaceuticals market value forecast: $ billion, 2011–16 46
Table 28: United States size of population (million), 2007–11 55
Table 29: United States gdp (constant 2000 prices, $ billion), 2007–11 55
Table 30: United States gdp (current prices, $ billion), 2007–11 55
Table 31: United States inflation, 2007–11 56
Table 32: United States consumer price index (absolute), 2007–11 56
Table 33: United States exchange rate, 2007–11 56
Table 34: Johnson & Johnson: key facts 57
Table 35: Johnson & Johnson: key financials ($) 58
Table 36: Johnson & Johnson: key financial ratios 58
Table 37: Pfizer Inc.: key facts 60
Table 38: Pfizer Inc.: key financials ($) 61
Table 39: Pfizer Inc.: key financial ratios 61
Table 40: AstraZeneca PLC: key facts 63
Table 41: AstraZeneca PLC: key financials ($) 64
Table 42: AstraZeneca PLC: key financial ratios 65
Table 43: Eli Lilly and Company: key facts 67
Table 44: Eli Lilly and Company: key financials ($) 68
Table 45: Eli Lilly and Company: key financial ratios 68
Table 46: Pfizer Inc.: key facts 70
Table 47: Pfizer Inc.: key financials ($) 71
Table 48: Pfizer Inc.: key financial ratios 71
Table 49: GlaxoSmithKline Plc: key facts 73
Table 50: GlaxoSmithKline Plc: key financials ($) 74
Table 51: GlaxoSmithKline Plc: key financials (L) 75
Table 52: GlaxoSmithKline Plc: key financial ratios 75
Table 53: Johnson & Johnson: key facts 77
Table 54: Johnson & Johnson: key financials ($) 78
Table 55: Johnson & Johnson: key financial ratios 78
Table 56: Pfizer Inc.: key facts 80
Table 57: Pfizer Inc.: key financials ($) 81
Table 58: Pfizer Inc.: key financial ratios 81
Table 59: GlaxoSmithKline Plc: key facts 83
Table 60: GlaxoSmithKline Plc: key financials ($) 84
Table 61: GlaxoSmithKline Plc: key financials (L) 85
Table 62: GlaxoSmithKline Plc: key financial ratios 85
Table 63: Merck & Co., Inc.: key facts 87
Table 64: Merck & Co., Inc.: key financials ($) 88
Table 65: Merck & Co., Inc.: key financial ratios 88

LIST OF FIGURES
Figure 1: Canada pharmaceuticals market value: $ billion, 2007–11 13
Figure 2: Canada pharmaceuticals market geography segmentation: % share, by value, 2011 14
Figure 3: Canada pharmaceuticals market share: % share, by value, 2011 15
Figure 4: Canada pharmaceuticals market value forecast: $ billion, 2011–16 16
Figure 5: Forces driving competition in the pharmaceuticals market in Canada, 2011 17
Figure 6: Drivers of buyer power in the pharmaceuticals market in Canada, 2011 18
Figure 7: Drivers of supplier power in the pharmaceuticals market in Canada, 2011 20
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2011 21
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2011 23
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2011 24
Figure 11: Mexico pharmaceuticals market value: $ billion, 2007–11 28
Figure 12: Mexico pharmaceuticals market geography segmentation: % share, by value, 2011 29
Figure 13: Mexico pharmaceuticals market share: % share, by value, 2011 30
Figure 14: Mexico pharmaceuticals market value forecast: $ billion, 2011–16 31
Figure 15: Forces driving competition in the pharmaceuticals market in Mexico, 2011 32
Figure 16: Drivers of buyer power in the pharmaceuticals market in Mexico, 2011 33
Figure 17: Drivers of supplier power in the pharmaceuticals market in Mexico, 2011 35
Figure 18: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2011 36
Figure 19: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2011 38
Figure 20: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2011 39
Figure 21: United States pharmaceuticals market value: $ billion, 2007–11 43
Figure 22: United States pharmaceuticals market geography segmentation: % share, by value, 2011 44
Figure 23: United States pharmaceuticals market share: % share, by value, 2011 45
Figure 24: United States pharmaceuticals market value forecast: $ billion, 2011–16 46
Figure 25: Forces driving competition in the pharmaceuticals market in the United States, 2011 47
Figure 26: Drivers of buyer power in the pharmaceuticals market in the United States, 2011 48
Figure 27: Drivers of supplier power in the pharmaceuticals market in the United States, 2011 50
Figure 28: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2011 51
Figure 29: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2011 53
Figure 30: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2011 54
Figure 31: Johnson & Johnson: revenues & profitability 58
Figure 32: Johnson & Johnson: assets & liabilities 59
Figure 33: Pfizer Inc.: revenues & profitability 62
Figure 34: Pfizer Inc.: assets & liabilities 62
Figure 35: AstraZeneca PLC: revenues & profitability 65
Figure 36: AstraZeneca PLC: assets & liabilities 66
Figure 37: Eli Lilly and Company: revenues & profitability 69
Figure 38: Eli Lilly and Company: assets & liabilities 69
Figure 39: Pfizer Inc.: revenues & profitability 72
Figure 40: Pfizer Inc.: assets & liabilities 72
Figure 41: GlaxoSmithKline Plc: revenues & profitability 75
Figure 42: GlaxoSmithKline Plc: assets & liabilities 76
Figure 43: Johnson & Johnson: revenues & profitability 78
Figure 44: Johnson & Johnson: assets & liabilities 79
Figure 45: Pfizer Inc.: revenues & profitability 82
Figure 46: Pfizer Inc.: assets & liabilities 82
Figure 47: GlaxoSmithKline Plc: revenues & profitability 85
Figure 48: GlaxoSmithKline Plc: assets & liabilities 86
Figure 49: Merck & Co., Inc.: revenues & profitability 88
Figure 50: Merck & Co., Inc.: assets & liabilities 89


Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.